Jeff Craven

Improving Cardiovascular and Renal Outcomes in T2D Patients: GLP-1 Agonists, SGLT2 Inhibitors

08/26/2019

Recent trials of GLP-1 receptor agonists and SGLT2 inhibitors have shown these drug classes could reduce or prevent cardiovascular and renal disease, improving outcomes despite their high cost.

Recent trials of GLP-1 receptor...

08/26/2019

First Report Managed Care

Literature Review

Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer

09/16/2021

Jeff Craven ;

In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...

In this literature review, we...

09/16/2021

First Report Managed Care

Digital Medicines: A Solution to Medication Nonadherence?

04/19/2019

Jeff Craven ;

Could medication with built-in digital sensors improve medication adherence and reduce health care costs? Experts discuss the potential benefits of novel digital medicines against privacy concerns of large-scale data collection.

Could medication with built-in...

04/19/2019

First Report Managed Care

Cover Story

Can Cost-Plus Pricing Lower the Cost of Generic Drugs for Patients?

04/18/2022

Jeff Craven ;

With the ever-rising costs of medications, new business models and patient care initiatives are becoming increasingly common methods to disrupt the industry to instill lasting change. But how do these recent ventures, like Mark Cuban’s new...

With the ever-rising costs of...

04/18/2022

First Report Managed Care

Big Pharma Embraces Big Data: What This Means for Payers and Patients

11/16/2018

Jeff Craven ;

Pharmaceutical companies are increasingly using big data techniques to improve outcomes, streamline the drug clinical pipeline and gain insight into new therapies. But real innovation may change how drug developers, payers, and providers...

Pharmaceutical companies are...

11/16/2018

First Report Managed Care

A Novel—And Cost-Effective—Approach to End-Stage Renal Disease

09/18/2018

Jeff Craven ;

Studies have shown success with hepatitis C-positive kidney transplantation in patients with end-stage renal disease followed by treatment with direct-acting antivirals to cure the infection. Experts discuss why this approach is not only...

Studies have shown success with...

09/18/2018

First Report Managed Care

Innovating Payment Models For Gene Therapy

08/30/2018

Jeff Craven ;

Gene therapy is a transformational treatment for some patients to potentially cure or prevent rare diseases. But questions still remain about how these drugs should be priced and who will pay for them.

Gene therapy is a...

08/30/2018

First Report Managed Care

Formulary Frontlines®

New Options Available for Treatment-Resistant Depression

11/20/2020

Jeff Craven ;

Over the past 30 years, few new pharmacologic therapies have been developed for mood disorders, including depression. However, for patients who do not respond to conventional pharmacologic treatments for MDD, new answers for...

Over the past 30 years, few new...

11/20/2020

First Report Managed Care

Breakthroughs Needed to Combat Antibiotic Resistance

07/23/2019

Jeff Craven ;

Pharmaceutical developments are not keeping pace with mutations in antibiotics; and, while international stakeholders recognize the severity of antimicrobial resistance, new breakthroughs in technology are needed to combat this threat.

Pharmaceutical developments are...

07/23/2019

First Report Managed Care

Drug Shortages Continue: The Effect on Care for Patients in Managed Care Settings

01/28/2019

Jeff Craven ;

Drug shortages have been more prevalent in recent years. Now, the US Food and Drug Administration (FDA), pharmaceutical companies, and other stakeholders are beginning to work together to open conversations about the issue’s causes and...

Drug shortages have been more...

01/28/2019

First Report Managed Care